Status of antibiotics resistance in h pylori infection
Reading File
Finding Sources
Searching PubMed
"Helicobacter pylori" AND "antibiotic resistance"
Searching the Web
H pylori antibiotic resistance status 2025 clarithromycin metronidazole global rates
Finding Sources
Reading Article
PMID: 38898622
Reading Article
PMID: 37972625
Finding Sources
Reading Web Page
https://gut.bmj.com/content/gutjnl/74/10/1561.full.pdf
Reading Article
PMID: 39710669
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive data from textbooks (Yamada's Gastroenterology, Harrison's 22e), the landmark Gut 2025 paper, and multiple recent meta-analyses. Let me compile the full answer.
Antibiotic Resistance in Helicobacter pylori Infection: Current Status (2025–2026)
Overview
H. pylori antibiotic resistance has reached globally alarming levels and is the primary driver of eradication failure. The WHO has classified H. pylori as a high-priority pathogen for research and new drug development. Resistance varies widely by region, antibiotic class, patient age, and prior treatment history, but the trend is universally upward.
Key Antibiotics and Their Resistance Rates
1. Clarithromycin
The most clinically consequential resistance. Clarithromycin failure renders the agent completely useless for further treatment (unlike metronidazole, which retains partial activity).
Global rates (2025 data, Gut 2025 survey):
| Region | Clarithromycin Resistance |
|---|---|
| Europe | 12-22.4% (rising >10% in 10 yrs) |
| North America (USA) | 16.7-31.4% (rising sharply - from 20.4% in 2000-05 to 49.5% in 2020-23) |
| Asia-Pacific (overall 1990-2022) | 22% overall; latest estimates 30% |
| Africa | 13.6-66.7% |
| South America | 14.4-31.3% |
| Turkey (highest in Europe) | up to 85% |
The Gut 2025 global survey (Schulz et al.) found clarithromycin resistance exceeds 15% in 24 of 31 countries surveyed. A 15% threshold is the key clinical decision point - above this, clarithromycin-based triple therapy should not be prescribed empirically.
The Lancet Gastroenterology & Hepatology 2024 Asia-Pacific meta-analysis (Hong et al., PMID 37972625, 351 studies, n=175 new) found the latest clarithromycin resistance at 30% (95% CI 28-33%) in the Asia-Pacific region - up from 22% overall 1990-2022.
Mechanism: Point mutations in the 23S rRNA gene (most commonly A2142G, A2143G), which prevent clarithromycin from binding its ribosomal target. These mutations arise from prior macrolide use for other infections (e.g., respiratory infections).
2. Metronidazole
The most prevalent resistance globally, but clinically "partial" - metronidazole-containing regimens are reduced in efficacy by only ~10% even with resistant strains, so it remains usable (Yamada's Gastroenterology, 7th ed).
Global rates:
| Region | Metronidazole Resistance |
|---|---|
| Asia-Pacific (latest) | 61% (55-66%), up from 52% overall |
| Africa | 62.7-100% |
| Europe | 17-62.4% |
| North America | 29.3-36.3% |
| South America | ~54% |
Children show lower rates (35.3% globally; BMC Medicine 2024 meta-analysis, PMID 39710669, 63 studies, n=15,953).
Mechanism: Loss-of-function mutations in the rdxA (nitroreductase) and frxA genes, which normally activate metronidazole within the bacterial cell. However, because multiple activation pathways exist, resistance is not absolute.
3. Levofloxacin (Fluoroquinolones)
Rapidly rising resistance tied to widespread quinolone use for urinary and respiratory infections.
Global rates:
| Region | Levofloxacin Resistance |
|---|---|
| Europe | 13-20.3% (rising) |
| North America | 31.9-42.6% |
| Asia-Pacific (latest) | 35% (31-39%) |
| Africa | 20-65.7% |
Levofloxacin resistance, like clarithromycin, renders the drug ineffective and it should be avoided in patients with prior fluoroquinolone exposure. Exceeds 15% in 18 of 31 countries (Gut 2025).
Mechanism: Point mutations in gyrA (DNA gyrase subunit A gene) at positions 87 and 91, preventing quinolone binding to its target.
4. Amoxicillin
Remains the most reliably active antibiotic globally - the "exception" to the resistance trend.
- Resistance <2% in 14 of 31 countries (Gut 2025)
- Asia-Pacific: 4-6% overall; latest ~6%
- Important exception: Africa, where amoxicillin resistance exceeds 90% in some countries (Egypt: 81.9-95%; Nigeria: 30-90.8%; Ethiopia: 91.7%)
Mechanism: Mutations in penicillin-binding proteins (PBP1A encoded by pbp1A gene), reducing amoxicillin affinity. Fortunately rare outside certain regions.
5. Tetracycline
Consistently low resistance globally (2-5% in most regions), making it a reliable component of bismuth quadruple therapy.
- Asia-Pacific: 4% overall
- Africa: 2.9-37.5% (higher variability)
6. Rifampicin/Rifabutin
Low overall resistance (0-4.3% in Europe; 22.8% in some Asia-Pacific countries), used as a rescue option in third-line regimens. Resistance can emerge rapidly.
Multi-Drug Resistance (MDR)
MDR - defined as resistance to 3 or more antibiotic classes - is a growing global threat:
- Among clarithromycin-resistant isolates, 75% are also resistant to metronidazole (data from US studies)
- The most common MDR profile globally: clarithromycin + metronidazole + levofloxacin
- Primary MDR rates remain ≤10% in many European countries but exceed 40% in some countries (e.g., Peru)
- MDR mechanisms include coccoid transformation (dormant form evades antibiotics), efflux pump upregulation, and biofilm formation
Why Is Resistance Rising?
As explained in Yamada's Textbook of Gastroenterology (7th ed.) and confirmed by current data:
- Antibiotic use for other infections - Clarithromycin resistance tracks macrolide consumption for chest infections; levofloxacin resistance tracks quinolone use for UTIs/respiratory infections
- Secondary resistance acquisition - Each failed treatment round selects for resistant mutants, and resistance can be acquired rapidly during treatment
- Lack of surveillance - Many countries lack national H. pylori reference laboratories or resistance monitoring programs
- Over-the-counter antibiotic access - Especially in low/middle-income countries driving high resistance in Asia and Africa
Clinical Implications
| Clinical Scenario | Recommendation |
|---|---|
| Clarithromycin resistance <15% locally | Standard triple therapy (PPI + clarithromycin + amoxicillin/metronidazole) acceptable |
| Clarithromycin resistance >15% | Bismuth-based quadruple therapy OR concomitant 4-drug therapy as first-line |
| Prior clarithromycin exposure | Avoid clarithromycin in subsequent regimens |
| Prior fluoroquinolone exposure | Avoid levofloxacin |
| Treatment failure twice | Endoscopy + culture + susceptibility-guided therapy (Harrison's 22e) |
| Northwestern Europe | Only region where clarithromycin triple therapy may still be used empirically |
Key point from Harrison's Principles of Internal Medicine 22e (2025): "In most parts of the world, the rate of primary macrolide resistance is sufficiently high that regimens containing clarithromycin plus one other antibiotic often fail." Vonoprazan (a potassium-competitive acid blocker) combined with amoxicillin ± clarithromycin has shown higher eradication rates than PPI-based regimens and represents an emerging strategy.
Surveillance and Testing
- The Gut 2025 survey found PCR-based resistance tests are used in 16/26 countries but reimbursed in only 4
- Next-generation sequencing (NGS) tests are available but not reimbursed in most countries
- Over 1 billion people worldwide have no access to bismuth-based regimens
- Routine susceptibility testing before first-line treatment is generally not recommended (requires endoscopy), but should be considered after second-line failure
Summary Table: Global Primary Resistance Rates (2024-2025)
| Antibiotic | Global Range | Threshold for Empiric Use | Trend |
|---|---|---|---|
| Clarithromycin | 7-92% | >15% = avoid empirically | ↑↑ |
| Metronidazole | 17-100% | >40% use with caution | ↑ |
| Levofloxacin | 13-66% | >15% = avoid empirically | ↑↑ |
| Amoxicillin | <2-95% | Generally safe (except Africa) | Stable |
| Tetracycline | 2-37% | Generally reliable | Stable |
| Rifabutin | 0-23% | Reserve for salvage | Stable |
Key References:
- Schulz C et al., Gut 2025 - Global resistance survey 2018-2023 (31 countries)
- Hong TC et al., Lancet Gastroenterol Hepatol 2024 - Asia-Pacific meta-analysis (PMID 37972625)
- Yu Y et al., Helicobacter 2024 - Global 10-year meta-analysis 163 studies (PMID 38898622)
- Salahi-Niri A et al., BMC Med 2024 - Pediatric global meta-analysis (PMID 39710669)
- Harrison's Principles of Internal Medicine 22e (2025), Chapter 168
- Yamada's Textbook of Gastroenterology, 7th ed., Chapter on H. pylori therapy
This is a shared conversation. Sign in to Orris to start your own chat.